This is the authors' abstract. We don't add key points for this paper.
A 59-year-old patient with type 2 diabetes, dyslipidemia, and hypertension underwent the placement of a duodenojejunal bypass (EndoBarrier; GI Dynamics, Boston, Massachusetts, USA). At the time of the endoscopy procedure, the patient weighed 110 kg and was 172 cm tall, resulting in a body mass index (BMI) of 37.3 kg/m2. The procedure, performed under general anesthesia, concluded without complications. Postoperatively, the patient was prescribed 40 mg of proton pump inhibitors (PPIs) twice daily and advised to avoid fiber. Early side effects included daily nausea (five to eight episodes), and epigastric pain was managed with antiemetics and ongoing PPI use. One month later, an endoscopy confirmed the duodenojejunal bypass was correctly positioned but revealed ulcers at the device's sharp edges. Despite initial challenges, symptoms improved significantly within three weeks. After 12 months, the patient had lost 30 kg, reducing their (BMI) to 27.3 kg/m2. The patient chose to keep the bypass despite the conclusion of the study and against medical advice about potential risks.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Král et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: